of the patents, an important event in patent litigation. The company has outstanding patent disputes with Abbott Labs, Affymetrix , Agilent, Becton Dickinson, Gen-Probe, Hologic, Ilumina, Life Technologies, Luminex, Roche and Seimens. Post your
Affymetrix ( AFFX -0.5% ) Q2 results : Total Revenue: $85.4M (+7.4%); Operating Expenses: $85.7M (+4.0%); Operating Loss
Affymetrix ( AFFX ): Q1 EPS of $0.01 beats by $0.01 . Revenue of $77.9M misses by $2.06M . ( PR ) Post your comment!
(Reuters) - Affymetrix Inc estimated third-quarter revenue that was below Wall Street expectations, as tightening academic funding worldwide reduced sales at its gene expression and eBioscience...
We are no longer providing equity research on Affymetrix AFFX . We provide broad coverage of more than 1,700 companies across more than 140 industries and adjust our coverage as necessary based on client demand and investor interest.
(Reuters) - Shares of Affymetrix Inc fell about 20 percent on Thursday, a day after the genetic analysis products maker reported preliminary second-quarter revenue below market expectations.
Affymetrix has faced pricing pressure on its consumables ..... a device in the sequencing market, Affymetrix has missed out on a high-growth research ..... manufacturing difficulties may have harmed Affymetrix 's reputation and prompted customers
Affymetrix AFFX swung to profitability in the third ..... needle on our fair value estimate. Affymetrix reported $74 million in sales, 5 ..... cancer research. On the capital front, Affymetrix has continued to repurchase its convertible
Affymetrix AFFX reported second-quarter results with revenue that came within its ..... Diagnostics to launch a colorectal cancer test. These efforts underpin Affymetrix 's efforts to focus investments on validation and diagnostic testing
Affymetrix AFFX today lowered its second-quarter revenue outlook to a range of $71 ..... decline. Lower second-quarter revenue will make it difficult for Affymetrix to achieve our full-year sales projections, and we are considering